Form 4: Vaccinex Director Jacob Frieberg Reports Stock Option Grants and Holdings

Director Jacob Frieberg reports stock option grants and adjustments following a reverse stock split at Vaccinex, Inc.

Summary

• Jacob Frieberg, a director of Vaccinex, Inc., filed a Form 4 detailing changes in his beneficial ownership.
• The report includes grants of stock options and adjustments to existing holdings due to a 1-for-14 reverse stock split that occurred on February 19, 2024.
• Frieberg received 2,211 stock options on May 10, 2024, in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024, with an exercise price of $5.75.
• He also received 10,108 stock options on May 10, 2024, under the Company's 2018 Omnibus Incentive Plan, also with an exercise price of $5.75.
• The options have various expiration dates, generally expiring five years following retirement or cessation of services, or on specific dates in the future.
• Frieberg also indirectly owns common stock through Benbow Estates, Ltd. (451 shares) and Gee Eff Services Limited (920 shares).

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The grant of options could be seen as a positive sign of alignment between management and shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The director elected to receive options in lieu of cash, showing confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements beyond the expiration dates of the stock options.

Industry Context

This filing is a routine disclosure related to insider transactions and equity compensation, common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in biotech companies, often used to align management's interests with shareholder value.
• The terms of the options, such as vesting schedules and expiration dates, are generally consistent with industry practices.
• Comparing the size of the grant to similar companies would require further analysis of Vaccinex's compensation policies and market capitalization.

Stakeholder Impact

• Shareholders: The grant of stock options can align the interests of the director with those of shareholders.
• Employees: The 2018 Omnibus Incentive Plan suggests broader employee equity participation.

Key Dates

Keywords

Vaccinex, VCNX, Form 4, Stock Options, Director, Jacob Frieberg, Reverse Stock Split, Beneficial Ownership